Table 3.

Estimated parameter values of the verinurad and XOI uric acid model

Parameter	Typical value	RSE %
$k_{\mathrm{in}}$, (mg/h)	43.78	1.75
FEUA, healthy volunteers	0.0906	3.18
CLI (L/h)	0.2272	12.8
V1, uric acid (L)	14.11	0.661
Verinurad EC50 (ng/mL)	29.40	4.73a
Febuxostat EC50 (ng/mL)	128.0	7.16a
Oxypurinol EC50 (ng/mL)	13,030	12a
Residual error, additive, serum	0.4107	0.158
Residual error, additive, urine	3.054	0.537
Residual error, proportional, urine	0.3806	0.371
Residual error, additive, serum study D5495C00006	0.9524	2.4
FEUA covariate, asymptomatic hyperuricemic	− 0.1501	32.2
FEUA covariate, symptomatic hyperuricemic (gout)	− 0.3787	6.06
FEUA covariate, Asians	− 0.2322	11.5
Verinurad EC50 covariate, symptomatic hyperuricemic (gout)	0.2677	33.5
$k_{\text{in}}$, IIV (CV%)	27.76	3.34
FEUA, IIV, (CV%)	42.54	3.98
Verinurad EC50, IIV, (CV%)	57.00	3.05
Febuxostat EC50, IIV, (CV%)	89.96	3.40
Oxypurinol EC50, IIV, (CV%)	65.44	9.66
Off diagonal element production rate—FEUA, (cor)	0.761	4.20

The covariate effect on FEUA was modelled as: FEUA = FEUA_TYP * (1 + HYPERFEUA) * (1 + ASIANFEUA), where FEUA_TYP corresponds to FEUA in healthy volunteers and HYPERFEUA and ASIANFEUA are the covariate estimates corresponding to hyperuricemic (either symptomatic or asymptomatic) and Asians, respectively

The covariate effect on verinurad EC50 was modelled as: EC50 = EC50_TYP *(1 + HYPEREC50), where EC50_TYP corresponds to EC50 in healthy volunteers and HYPEREC50 corresponds to the covariate estimate for symptomatic hyperuricemic (gout) patients

CL_I intestinal clearance of uric acid, FEUA fractional excretion uric acid (here, reported as fraction), HYPEREC50 verinurad EC50 covariate in symptomatic hyperuricemic patients, IIV interindividual variability, k_in uric acid production rate, R_P uric acid production rate, RSE relative standard error, V₁ volume of distribution

^aEstimated on log-scale and reported as CV%